Covidien, a leading global provider of healthcare products, today announced that its surgical devices business unit has introduced the VascuSeal vascular sealant system throughout Europe.
VascuSeal offers surgeons a unique advanced hydrogel that provides an immediate, blood-tight seal that is effective intraoperatively and throughout the critical healing period.
VascuSeal, which is CE-marked, is intended for use as a surgical sealant during arterial and venous reconstructions to seal suture lines.
Unlike a haemostatic agent, a vascular sealant can seal blood leaks and does not depend on either the time for the blood to clot or the strength of the blood clot to perform successfully.
The VascuSeal sealant system offers surgeons a valuable tool to reduce bleeding from the suture line in vascular bypass procedures, and reduces post-operative complications associated with suture line bleeding.
“The VascuSeal vascular sealant system represents another innovative product in the BioSurgery marketplace,” said Scott Flora, President, Surgical Devices, Covidien.
“We expect VascuSeal to be well-received by surgeons looking to improve patient outcomes, save time and reduce blood loss during surgical procedures.”
